When every patient matters, you can't afford to lose a single lead
Tiny eligible populations, geographic dispersion, and limited site bandwidth make rare disease enrollment unforgiving. TrialScreen uses digital-first engagement and portfolio matching to make sure every lead gets screened — and no one falls through the cracks.
See How It Works →Why rare disease enrollment is unforgiving
There's no margin for error when your eligible population is measured in single digits.
Tiny Eligible Populations
Some rare disease trials have single-digit eligible patients per site. Every lead is irreplaceable, and losing one to a missed call or slow follow-up can delay the entire program.
Geographic Dispersion
Eligible patients are spread across wide geographic areas. Traditional in-person screening models don’t scale when patients are hundreds of miles from your site.
Limited Site Bandwidth
Sites running one or two rare disease studies often lack dedicated recruitment staff. Coordinators juggle screening alongside clinical duties, and outreach falls through the cracks.
How TrialScreen protects every lead
Portfolio Matching Maximizes Every Interaction
When every patient counts, you can’t afford to screen for one trial at a time. TrialScreen evaluates each participant against every active protocol in your portfolio in a single conversation.
Digital-First Engagement
SMS-based screening reaches geographically dispersed patients without requiring travel. Participants complete prescreening from anywhere, on their own schedule, over text.
Protocol Intelligence for Feasibility
TrialScreen parses complex rare disease protocols and helps assess feasibility before you commit resources. Criterion-level matching shows exactly where candidates meet or miss requirements.
The rare disease enrollment crisis
of sites enroll zero patients
Clinical Leader, 2025
of trials fail to meet enrollment targets
JMIR, 2020
of US adults participate in clinical trials
NIH
See how TrialScreen handles rare disease protocols
Book a demo and we'll show you how portfolio matching and digital-first engagement work for small patient populations.